MORC3 and myositis disease: A retrospective cohort study demonstrated associations between anti-transcription intermediary factor 1 (TIF1)-γ and anti-nuclear matrix protein 2 (NXP2) antibodies with stage III+ cancer-associated myositis (CAM) (21).